Denali Therapeutics Inc. (Nasdaq: DNLI) has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Mergers and Acquisitions